Having trouble accessing articles? Reset your cache.

Amgen beats on EPS but misses on revenues

Shares of Amgen Inc. (NASDAQ:AMGN) slid $6.78 to $105.98 in early after-hours trading after the biotech reported 1Q13 earnings that beat on EPS but missed on revenues. Amgen reported 1Q13 adjusted diluted

Read the full 327 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE